Cervarix Proving Effective against HPV Cambridge MA

The human papillomavirus (HPV) vaccine Cervarix protects women from infection for longer than six years, new research has found. The vaccine guards against the two types of HPV (HPV-16 and HPV-18) most commonly associated with cervical cancer.

Cambridge Medical Associates
(617) 491-5586
575 Mount Auburn St
Cambridge, MA
 
Potter Patricia
(617) 576-2826
1280 Maschsts Ave
Cambridge, MA
 
Workum Susan Phys
(617) 354-1291
70 Fayerweather St
Cambridge, MA
 
Jacobs Sharon MD
(617) 492-7245
129 Mount Auburn St
Cambridge, MA
 
Feldman Jamie MD
(617) 661-2590
6 Garden Ter
Cambridge, MA
 
Ornstein Mariam MD
(617) 441-8751
Cambridge, MA
 
Hogan Marion
(617) 868-4928
300 Mount Auburn St
Cambridge, MA
 
Nolan Jas A MD
(617) 576-3057
237 Hampshire St
Cambridge, MA
 
Lacy Steven MD
(617) 576-3057
237 Hampshire St
Cambridge, MA
 
McRae Simon MD
(617) 665-2555
1493 Cambridge St
Cambridge, MA
 

Cervarix Proving Effective against HPV

Provided By:

WEDNESDAY, Dec. 2 (HealthDay News) -- The human papillomavirus (HPV) vaccine Cervarix protects women from infection for longer than six years, new research has found.

The vaccine guards against the two types of HPV (HPV-16 and HPV-18) most commonly associated with cervical cancer.

The study looked at nearly 800 women, aged 15 to 25, with a normal cervical profile and no evidence of HPV infection at the start of the trial. There were 393 women who received the Cervarix vaccine and 383 who received an inactive placebo. Every six months for 6.4 years, the women were tested for HPV DNA.

The researchers found that vaccine efficacy against 12-month persistent infection with HPV-16/18 remained 100 percent during the study period. Vaccine efficacy against incident infection with HPV-16/18 was 95 percent. Antibody concentrations against HPV-16/18 in vaccinated women remained at least several-fold higher than would be found after natural HPV infection, the study authors noted.

Cervarix also protected women against incident infection with HPV-31 and HPV-45, which "are among the types most frequently associated with cervical cancer after HPV-16 and HPV-18, and are responsible for 10 percent of all cervical cancer cases," wrote Dr. Cosette Wheeler, of the Health Sciences Center at the University of New Mexico, and colleagues.

The study was released online Dec. 2 in advance of publication in an upcoming print issue of The Lancet.

"Although further assessment is necessary to confirm long-term vaccine effects, in view of the data from our study, we expect protection to continue for many more years," the researchers concluded.

Cervarix, from GlaxoSmithKline, received U.S. Food and Drug Administration approval in October.

More information

The U.S. National Cancer Institute has more about HPV vaccines.

SOURCE: The Lancet, news release, Dec. 2, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com